Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Ultrasound-Guided procedure could reduce bleeding risk in cirrhosis patients

NCT ID NCT07354789

Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new procedure using an endoscopic ultrasound to guide the injection of tiny particles into the spleen, reducing blood flow and lowering the risk of dangerous bleeding in people with liver cirrhosis. The goal is to see if this method is safer and more effective than traditional X-ray-guided treatments. About 50 adults with cirrhosis, low platelets, and a history of stomach bleeding will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18-80 years. 2. Diagnosis of liver cirrhosis based on clinical, laboratory, and imaging examinations. 3. Complicated with gastrointestinal bleeding caused by esophagogastric varices. 4. Patients with hypersplenism and thrombocytopenia (platelet count \< 100 × 10\^9/L). Exclusion Criteria: 1. Patients who have previously undergone splenectomy, PSE, transjugular intrahepatic portosystemic shunt (TIPS), varicocelectomy, sclerotherapy, or balloon-occluded retrograde transvenous obliteration. 2. Hepatocellular carcinoma or other malignant tumors. 3. Patients with hepatic encephalopathy who are unable to cooperate, or those with liver failure or a Child-Pugh score \>13. 4. Patients with allergies to intravenous anesthetics. 5. Patients with unstable vital signs, associated organ dysfunction, active infection, or cardiopulmonary insufficiency, who cannot tolerate endoscopy. 6. Patients who are unable or unwilling to provide informed consent. 7. Uncorrectable coagulation disorders (INR \>1.5 and/or fibrinogen \<120 mg/dL) or uncorrectable thrombocytopenia (platelet count \<20 × 10\^9/L). 8. Patients who have used beta-blockers within the past 24 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices with bleeding Fibrosis Hemorrhage hemorrhagic disease hypersplenism portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding Cirrhosis Portal hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.